Drug Target Review
DECEMBER 12, 2023
We use hydrophilic linkers, which prevent ADC aggregation and generate highly stable ADCs, in combination with a unique attachment site on the antibody to create ADCs that retain pharmacokinetic properties similar to the original unconjugated antibody. This helps to maximize the targeted payload delivery to tumor cells.
Drug Target Review
OCTOBER 24, 2023
When introduced into another ecosystem the strains in our LBP are subject to cooperation, competition and antagonism from other microorganisms and the host, which means that the pharmacokinetics and pharmacodynamics of the drug are somewhat more dynamic than might be expected for traditional pharmaceuticals. difficile and C. albicans.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Alta Sciences
OCTOBER 30, 2023
In this in-depth discussion on the FDA’s June draft guidance on clinical investigation of psychedelic drugs, Doctors Denise Milovan, Debra Kelsh, and Beatrice Setnik share insights into the potential need for additional methodological adaptations for study designs, in order to evaluate the safety and effects. Watch it now.
The Pharma Data
SEPTEMBER 8, 2021
Evaluation of the Pharmacokinetic Interaction and Safety of Coadministered Atogepant and Topiramate. Tell your doctor if you have any breathing-related problems. Tell your doctor if you have any breathing-related problems. Tell your doctor if you experience any problems with your eyes while receiving BOTOX ®. Ubrogepant.
The Pharma Data
JUNE 28, 2021
The filing of this application in the US is an important step in helping to address the burden of venous thromboembolism and provide doctors with body weight-based dosing options in pediatric patients,” said Dr Christian Rommel, Head of Research and Development and Member of the Executive Committee at Bayer Pharmaceuticals.
Agency IQ
SEPTEMBER 15, 2023
The committee also made recommendations regarding pharmacokinetic and safety assessments. When looking at several pharmacokinetic studies, the FDA found that the 10 mg oral dose of phenylephrine has a very low bioavailability of less than 1% and, subsequently, low systemic alpha-1 adrenergic activity. “We
The Pharma Data
DECEMBER 3, 2020
Safety and Pharmacokinetics of Antisense Oligonucleotide STK-001 in Children and Adolescents with Dravet Syndrome: Single and Multiple Ascending Dose Design for the Open-Label Phase 1/2a MONARCH Study. The primary endpoints are safety, tolerability and pharmacokinetic (PK) profile of STK-001 in Dravet syndrome patients.
Expert insights. Personalized for you.
114 
Let's personalize your content